Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 12 de 12
Filter
1.
Am J Physiol Renal Physiol ; 320(4): F559-F568, 2021 04 01.
Article in English | MEDLINE | ID: mdl-33615893

ABSTRACT

Hypercalciuria is one of the early manifestations of diabetic nephropathy (DN). This is partially due to a decrease in the expression of renal transient receptor potential vanilloid type 5 (TRPV5), which is responsible for renal Ca2+ reabsorption. Soluble klotho has been previously determined to increase TRPV5 by cleaving sialic acid, causing TRPV5 to bind to membrane protein galectin-1. However, a recent study showed that soluble klotho binds to α2-3-sialyllactose, where sialic acid is located, on TRPV5, rather than cleave it. Here, we report that soluble klotho tethers TRPV5 on the membrane by binding both TRPV5 and galectin-1, thereby protecting membrane TRPV5 from diabetes-induced endocytosis. In the present study, we injected recombinant soluble α-klotho protein (rKL) into db/db and db/m mice for 8 wk and collected urine and kidneys. We administered rKL, AZD4547 [fibroblast growth factor (FGF) receptor type 1 inhibitor], and OTX008 (galectin-1 inhibitor) to cultured mouse distal tubular cells with or without 30 mM high-glucose (HG) exposure. db/db mice showed increased renal Ca2+ excretion and decreased renal TRPV5 expression. rKL treatment reversed this change. In vitro, TRPV5 expression in distal tubular cells decreased under HG conditions, and rKL successfully upregulated TRPV5 with or without FGF23. Also, immunofluorescence showed colocalization of klotho, TRPV5, and galectin-1 in distal tubule cells, suggesting that klotho binds to both TRPV5 and galectin-1. Moreover, when both FGF receptor type 1 and galectin-1 were inhibited, rKL failed to increase TRPV5 under HG conditions. Our results indicate that soluble klotho prevents TRPV5 from degradation and subsequent diabetes-induced endocytosis by anchoring TRPV5 through binding with both TRPV5 and galectin-1.NEW & NOTEWORTHY Soluble α-klotho anchors transient receptor potential vanilloid type 5 (TRPV5) on the apical membrane of the distal tubule by binding both TRPV5 and a membrane-abundant protein, galectin-1. This newly discovered mechanism works even when fibroblast growth factor (FGF)23 signaling is inhibited by treatment with FGF receptor type 1 inhibitor. Therefore, we identified how soluble α-klotho increases TRPV5 without FGF23. We confirmed this mechanism by observing that soluble α-klotho fails to enhance TRPV5 when both FGF receptor type 1 and galectin-1 are inhibited.


Subject(s)
Calcium Channels/drug effects , Calcium Channels/metabolism , Cell Membrane/drug effects , Galectin 1/metabolism , Kidney/metabolism , TRPV Cation Channels/drug effects , TRPV Cation Channels/metabolism , Animals , Benzamides/pharmacology , Cell Membrane/metabolism , Diabetic Nephropathies/metabolism , Endocytosis/drug effects , Endocytosis/physiology , Epithelial Cells/metabolism , Fibroblast Growth Factor-23 , Fibroblast Growth Factors/metabolism , Galectin 1/pharmacology , Mice , N-Acetylneuraminic Acid/pharmacology , Piperazines/pharmacology , Pyrazoles/pharmacology
2.
Biochem Biophys Res Commun ; 509(3): 680-686, 2019 02 12.
Article in English | MEDLINE | ID: mdl-30616891

ABSTRACT

Cisplatin causes acute kidney injury (AKI) through proximal tubular injury. We investigated the protective effect of the adenosine monophosphate protein kinase (AMPK) activator 5-aminoimidazole-4-carboxamide ribonucleotide (AICAR) against cisplatin-induced AKI. We investigated whether the AMP-kinase activator AICAR ameliorates cisplatin-induced AKI through the JAK/STAT/SOCS pathway. Male Sprague-Dawley (SD) rats were randomly divided into four groups: control, AICAR, cisplatin, and cisplatin + AICAR. As appropriate to their treatment group, the rats were injected with a single dose of cisplatin (7 mg/kg, i.p.). AICAR was administered to the rats at 100 mg/kg i.p. daily. Blood urea nitrogen (BUN) and serum creatinine were measured. Renal damage was analyzed in sections stained with hematoxylin and eosin (H&E). Renal tissues were also examined by immunohistochemistry and western blot for p-AMPK, Kim-1, cleaved caspase 3, and JAK/STAT/SOCS. For in vitro studies, NRK-52E normal rat kidney cells were treated with cisplatin and/or AICAR. By western blot, we confirmed the expression of p-AMPK and the JAK/STAT/SOCS pathway in NRK-52E cells. AICAR was protective against cisplatin-induced acute tubular injury by up-regulating p-AMPK expression in NRK-52E cells. Protein expression levels of JAK2/STAT1 were markedly ameliorated in NRK-52E cells by AICAR. The protective mechanism of AICAR may be associated with suppression of the JAK2/STAT1 pathway and up-regulation of SOCS1, an inhibitor of the JAK2/STAT1 pathway. The present study demonstrates the protective effects of AICAR against cisplatin-induced AKI and shows a new renoprotective mechanism through the JAK2/STAT1/SOCS1 pathway and apoptosis inhibition. This study suggests that activation of the AMPK activator AICAR might ameliorate cisplatin-induced AKI.


Subject(s)
Acute Kidney Injury/chemically induced , Acute Kidney Injury/prevention & control , Aminoimidazole Carboxamide/analogs & derivatives , Antineoplastic Agents/adverse effects , Cisplatin/adverse effects , Enzyme Activators/therapeutic use , Ribonucleotides/therapeutic use , Signal Transduction/drug effects , AMP-Activated Protein Kinases/metabolism , Acute Kidney Injury/metabolism , Acute Kidney Injury/pathology , Aminoimidazole Carboxamide/therapeutic use , Animals , Cell Line , Janus Kinases/metabolism , Kidney/drug effects , Kidney/metabolism , Kidney/pathology , Male , Rats, Sprague-Dawley , STAT Transcription Factors/metabolism , Suppressor of Cytokine Signaling Proteins/metabolism
3.
PLoS One ; 13(8): e0201692, 2018.
Article in English | MEDLINE | ID: mdl-30161162

ABSTRACT

BACKGROUND: Renal fibrosis is characterized by excessive production and deposition of extracellular matrix (ECM), which leads to progressive renal failure. Adenosine-monophosphate-activated protein kinase (AMPK) is a highly conserved kinase that plays a key role in Smad-3 signaling. Here, we examined the effect of a novel AMPK activator, HL156A, on the inhibition of renal fibrosis in in vivo and in vitro models. METHODS: Unilateral ureteral obstruction (UUO) was induced in male Wistar rats. Rats with UUO were administered HL156A (20mg/kg/day), and then the kidneys were harvested 10 days after ligation for further analysis. RESULTS: In the rat UUO model, HL156A attenuated ECM protein deposition. After HL156A treatment, expressions of TGF-ß1, p-Smad3, α-SMA, fibronectin, and type IV collagen were suppressed, and E-cadherin expression was up-regulated. In the in vitro experiment, NRK52E cells were treated with HL156A before TGF-ß1 stimulation. The inhibitory effects of HL156A upon the signaling pathways and markers of the epithelial-to-mesenchymal transition (EMT) were analyzed. In TGF-ß1-treated NRK-52E cells, HL156A co-treatment inhibited the TGF-ß1-induced Smad3 signaling pathway and EMT markers. CONCLUSION: Taken together, the above findings suggest that HL156A, a novel AMPK activator, ameliorates renal fibrosis in vivo and in vitro.


Subject(s)
AMP-Activated Protein Kinases/metabolism , Guanidines/pharmacology , Kidney/drug effects , Kidney/pathology , Pyrrolidines/pharmacology , Ureteral Obstruction/pathology , Animals , Apoptosis/drug effects , Cell Line , Disease Models, Animal , Dose-Response Relationship, Drug , Enzyme Activation/drug effects , Fibrosis , Guanidines/therapeutic use , Kidney/metabolism , Pyrrolidines/therapeutic use , Rats , Rats, Wistar , Signal Transduction/drug effects , Smad3 Protein/metabolism , Time Factors , Transforming Growth Factor beta1/metabolism
4.
J Cancer Prev ; 22(3): 189-194, 2017 Sep.
Article in English | MEDLINE | ID: mdl-29018784

ABSTRACT

Cerulein-induced pancreatitis is similar to human edematous pancreatitis, characterized by the dysregulation of digestive enzyme production, edema formation, and an infiltration of inflammatory cells into the pancreas. We previously showed that the Janus kinase 2 (JAK2)/STAT3 pathway mediates inflammatory signaling in cerulein-stimulated pancreatic acinar cells. PPAR-γ has been implicated in the regulation of inflammatory responses in several cells. In the present study, we investigated the role of PPAR-γ in cerulein-induced activation of JAK2/STAT3 in pancreatic acinar cells. Treatment with cerulein induced the activation of JAK2/STAT3 and PPAR-γ expression in AR42J cells. Cerulein-induced PPAR-γ expression was inhibited by AG490, a JAK2/STAT3 inhibitor, in AR42J cells. An immunoprecipitation analysis showed that PPAR-γ binds to STAT3 in cerulein-stimulated AR42J cells. Down-regulation of PPAR-γ by siRNA increased STAT3 phosphorylation in AR42J cells stimulated with cerulein. These results show that PPAR-γ inactivates STAT3 by directly interacting with STAT3 in cerulein-stimulated pancreatic acinar cells. Overexpression of PPAR-γ may be beneficial for preventing pancreatitis by suppressing the activation of STAT3 in pancreatic acinar cells.

5.
Kidney Int ; 92(2): 415-431, 2017 08.
Article in English | MEDLINE | ID: mdl-28396117

ABSTRACT

Extracellular adenosine triphosphate (ATP) binds to purinergic receptors and, as a danger molecule, promotes inflammatory responses. Here we tested whether periodate-oxidized ATP (oATP), a P2X7 receptor (P2X7R) antagonist can attenuate renal ischemia-reperfusion injury and clarify the related cellular mechanisms. Treatment with oATP prior to ischemia-reperfusion injury decreased blood urea nitrogen, serum creatinine, the tubular injury score, and tubular epithelial cell apoptosis after injury. The infiltration of dendritic cells, neutrophils, macrophages, CD69+CD4+, and CD44+CD4+ T cells was attenuated, but renal Foxp3+CD4+ Treg infiltration was increased by oATP. The levels of IL-6 and CCL2 were reduced in the oATP group. Additionally, oATP treatment following injury improved renal function, decreased the infiltration of innate and adaptive effector cells, and increased the renal infiltration of Foxp3+CD4+ Tregs. Post-ischemia-reperfusion injury oATP treatment increased tubular cell proliferation and reduced renal fibrosis. oATP treatment attenuated renal functional deterioration after ischemia-reperfusion injury in RAG-1 knockout mice; however, Treg depletion using PC61 abrogated the beneficial effects of oATP in wild-type mice. Furthermore, oATP treatment after transfer of Tregs from wild-type mice improved the beneficial effects of Tregs on ischemia-reperfusion injury, but treatment after transfer of Tregs from P2X7R knockout mice did not. Renal ischemia-reperfusion injury was also attenuated in P2X7R knockout mice. Experiments using bone marrow chimeras established that P2X7R expression on hematopoietic cells rather than non-hematopoietic cells, such as tubular epithelial cells, plays a major role in ischemia-reperfusion injury. Thus, oATP attenuated acute renal damage and facilitated renal recovery in ischemia-reperfusion injury by expansion of Tregs.


Subject(s)
Acute Kidney Injury/prevention & control , Adenosine Triphosphate/analogs & derivatives , Purinergic P2X Receptor Antagonists/therapeutic use , Reperfusion Injury/prevention & control , T-Lymphocytes, Regulatory/drug effects , Acute Kidney Injury/immunology , Acute Kidney Injury/pathology , Adenosine Triphosphate/pharmacology , Adenosine Triphosphate/therapeutic use , Animals , Drug Evaluation, Preclinical , Fibrosis , Genes, RAG-1 , Immunity, Innate/drug effects , Kidney/drug effects , Kidney/pathology , Male , Mice, Inbred C57BL , Mice, Knockout , Purinergic P2X Receptor Antagonists/pharmacology , Receptors, Purinergic P2X7/metabolism , Reperfusion Injury/immunology , Reperfusion Injury/pathology
6.
Am J Physiol Renal Physiol ; 310(5): F342-50, 2016 Mar 01.
Article in English | MEDLINE | ID: mdl-26661649

ABSTRACT

HL156A is a novel AMP-activated protein kinase (AMPK) activator. We aimed to investigate the protective mechanism of HL156A against peritoneal fibrosis (PF) in in vivo and in vitro models. The rat PF model was induced by daily intraperitoneally injection of chlorhexidine (CHX) solution containing 0.1% CHX gluconate and 15% ethanol for 4 wk. The rats in the treatment group were treated with HL156A (1 mg·kg(-1)·day(-1)). Control rats were injected with vehicle alone. In vitro, cultured rat peritoneal mesothelial cells (RPMCs) were treated with either high glucose (HG; 50 mM), normal glucose (NG; 5 mM), NG+HL156A, or HG+HL156A. HL156A in supplemented rats ameliorated peritoneal calcification, cocoon formation, bowel obstruction, and PF. Immunohistochemistry showed reduced fibronectin accumulation in the peritoneum of HL156A-treated rats compared with those injected with CHX alone. HL156A treatment of RPMCs inhibited HG-induced myofibroblast transdifferentiation and markers of epithelial-mesenchymal transition (EMT). Moreover, HL156A ameliorated HG-induced transforming growth factor-ß1, Smad3, Snail, and fibronectin expression in the RPMCs via AMPK upregulation. These results suggest that HL156A exhibits a protective effect in PF progression. Further research is warranted to seek the therapeutic potential of HL156A as an antifibrotic agent in peritoneal dialysis patients.


Subject(s)
AMP-Activated Protein Kinases/metabolism , Enzyme Activators/pharmacology , Guanidines/pharmacology , Peritoneal Fibrosis/prevention & control , Peritoneum/drug effects , Pyrrolidines/pharmacology , AMP-Activated Protein Kinases/genetics , Animals , Cell Transdifferentiation/drug effects , Cells, Cultured , Chlorhexidine/analogs & derivatives , Cytoprotection , Disease Models, Animal , Dose-Response Relationship, Drug , Enzyme Activation , Enzyme Activators/chemical synthesis , Epithelial-Mesenchymal Transition/drug effects , Ethanol , Fibronectins/genetics , Fibronectins/metabolism , Glucose/metabolism , Guanidines/chemical synthesis , Male , Myofibroblasts/drug effects , Myofibroblasts/enzymology , Myofibroblasts/pathology , Peritoneal Fibrosis/chemically induced , Peritoneal Fibrosis/enzymology , Peritoneal Fibrosis/genetics , Peritoneal Fibrosis/pathology , Peritoneum/enzymology , Peritoneum/pathology , Pyrrolidines/chemical synthesis , RNA Interference , Rats, Wistar , Smad3 Protein/genetics , Smad3 Protein/metabolism , Snail Family Transcription Factors , Transcription Factors/genetics , Transcription Factors/metabolism , Transfection , Transforming Growth Factor beta1/genetics , Transforming Growth Factor beta1/metabolism
7.
Nephrology (Carlton) ; 17(5): 472-9, 2012 Jul.
Article in English | MEDLINE | ID: mdl-22435951

ABSTRACT

AIM: The mortality and morbidity of end-stage renal failure patients remains high despite recent advances in pre-dialysis care. Previous studies suggesting a positive effect of pre-dialysis education were limited by unmatched comparisons between the recipients and non-recipients of education. The present study aimed to clarify the roles of the multidisciplinary pre-dialysis education (MPE) in chronic kidney disease patients. METHODS: We performed a retrospective single centre study, enrolling 1218 consecutive pre-dialysis chronic kidney disease patients, between July 2007 and Feb 2008 and followed them up to 30 months. By using propensity score matching, we matched 149 recipient- and non-recipient pairs from 1218 patients. The incidences of renal replacement therapy, mortality, cardiovascular event and infection were compared between recipients and non-recipients of MPE. RESULTS: Renal replacement therapy was initiated in 62 and 64 patients in the recipients and non-recipients, respectively (P > 0.05). The MPE reduced unplanned urgent dialysis (8.7% vs 24.2%, P < 0.001) and shortened hospital days (2.16 vs 5.05 days/patient per year). MPE recipients had a better metabolic status at the time of initiating renal replacement therapy. Although no significant survival advantage from MPE was exhibited, MPE recipients had lower incidence of cardiovascular events (adjusted hazard ratio, 0.24; 95% confidence interval (CI), 0.08 to 0.78; P = 0.017), and a tendency toward a lower infection rate (adjusted hazard ratio, 0.44; 95% CI, 0.17 to 1.11; P = 0.083). CONCLUSION: MPE was associated with better clinical outcomes in terms of urgent dialysis, cardiovascular events and infection.


Subject(s)
Health Knowledge, Attitudes, Practice , Kidney Failure, Chronic/therapy , Patient Care Team , Patient Education as Topic , Adult , Aged , Cardiovascular Diseases/etiology , Cardiovascular Diseases/mortality , Chi-Square Distribution , Communicable Diseases/etiology , Communicable Diseases/mortality , Disease Progression , Female , Hospitalization , Humans , Incidence , Kaplan-Meier Estimate , Kidney Failure, Chronic/complications , Kidney Failure, Chronic/mortality , Length of Stay , Male , Middle Aged , Prognosis , Propensity Score , Proportional Hazards Models , Renal Replacement Therapy , Republic of Korea , Retrospective Studies , Risk Assessment , Risk Factors , Time Factors
8.
J Korean Med Sci ; 27(2): 170-6, 2012 Feb.
Article in English | MEDLINE | ID: mdl-22323864

ABSTRACT

Recent studies reported that early initiation of hemodialysis may increase mortality. However, studies that assessed the influence of early initiation of peritoneal dialysis (PD) yielded controversial results. In the present study, we evaluated the prognosis of early initiation of PD on the various outcomes of end stage renal failure patients by using propensity-score matching methods. Incident PD patients (n = 491) who started PD at SNU Hospital were enrolled. The patients were divided into 'early starters (n = 244)' and 'late starters (n = 247)' on the basis of the estimated glomerular filtration rate (eGFR) at the start of dialysis. The calculated propensity-score was used for one-to-one matching. After propensity-score-based matching (n = 136, for each group), no significant differences were observed in terms of all-cause mortality (P = 0.17), technique failure (P = 0.62), cardiovascular event (P = 0.96) and composite event (P = 0.86) between the early and late starters. Stratification analysis in the propensity-score quartiles (n = 491) exhibited no trend toward better or poorer survival in terms of all-cause mortality. In conclusion, early commencement of PD does not reduce the mortality risk and other outcomes. Although the recent guidelines suggest that initiation of dialysis at higher eGFR, physicians should not determine the time to initiate PD therapy simply rely on the eGFR alone.


Subject(s)
Kidney Failure, Chronic/mortality , Peritoneal Dialysis , Adult , Aged , Female , Glomerular Filtration Rate , Humans , Kidney Failure, Chronic/therapy , Male , Middle Aged , Prognosis , Propensity Score , Proportional Hazards Models , Retrospective Studies , Survival Rate , Treatment Outcome
9.
Am J Physiol Renal Physiol ; 302(5): F606-13, 2012 Mar 01.
Article in English | MEDLINE | ID: mdl-22129969

ABSTRACT

Pyruvate is an endogenous antioxidant and anti-inflammatory substance. The present study was implemented to investigate the protective effect of ethyl pyruvate (EP) against the development and progression of diabetic nephropathy in an in vivo and in vitro model. Diabetic rats were prepared by injecting streptozotocin (65 mg/kg). Those that developed diabetes after 72 h were treated with EP (40 mg/kg) intraperitoneally. Diabetic rats without pyruvate treatment and nondiabetic rats were used for control. As an in vitro experiment, rat mesangial cells cultured primarily from Sprague-Dawley rats were treated in high-glucose (HG; 50 mM) or normal-glucose (NG; 5 mM) conditions and with or without pyruvate. Pyruvate-treated diabetic rats exhibited decreased albuminuria and attenuated NADPH-dependent reactive oxygen species generation. Immunohistochemistry showed reduced laminin, type IV collagen, and fibronectin deposition in the glomeruli compared with nontreated diabetic rats. Parallel changes were shown in tissue mRNA and protein expression levels of monocyte chemoattractant protein-1, transforming growth factor-ß1, laminin, fibronectin, and type IV collagen in the kidney. Concordantly, protective effects were also exhibited in the mesangial cell culture system. These findings suggest that pyruvate protects against kidney injury via NADPH oxidase inhibition. The present study established that activation of NADPH oxidase plays a crucial role in diabetes-induced oxidative stress, glomerular hypertrophy, and ECM molecule expression. Pyruvate exhibited a renoprotective effect in the progression of experimental diabetic nephropathy. Future research is warranted to investigate the protective mechanism of pyruvate more specifically in relation to NADPH oxidase in diabetic nephropathy.


Subject(s)
Albuminuria/drug therapy , Diabetic Nephropathies/drug therapy , Kidney Glomerulus/drug effects , Pyruvates/therapeutic use , Albuminuria/metabolism , Albuminuria/physiopathology , Animals , Cells, Cultured , Chemokine CCL2/metabolism , Collagen Type IV/metabolism , Diabetes Mellitus, Experimental/metabolism , Diabetes Mellitus, Experimental/physiopathology , Diabetic Nephropathies/metabolism , Diabetic Nephropathies/physiopathology , Disease Progression , Fibronectins/metabolism , Kidney Glomerulus/metabolism , Kidney Glomerulus/physiopathology , Laminin/metabolism , Male , Mesangial Cells/cytology , Mesangial Cells/drug effects , Mesangial Cells/metabolism , NADPH Oxidases/metabolism , Oxidative Stress , Pyruvates/pharmacology , Rats , Rats, Sprague-Dawley , Reactive Oxygen Species/metabolism , Transforming Growth Factor beta1/metabolism
10.
Yonsei Med J ; 52(4): 588-94, 2011 Jul.
Article in English | MEDLINE | ID: mdl-21623600

ABSTRACT

PURPOSE: We conducted a multi-center randomized double-blind study to determine the effects of 6-month therapy with sulodexide on urinary protein excretion in patients with idiopathic Immunoglobulin A (IgA) nephropathy. MATERIALS AND METHODS: A total of seventy-seven patients participated in the study. They were randomly allocated to one of three groups: sulodexide 75 mg or 150 mg daily or the placebo for 6 months. The primary end point was the achievement, at 6 months, of at least 50% reduction in urine protein/creatinine ratio (UPCR) from the baseline value. RESULTS: At 6 months, the primary end point was achieved by 12.5% of the patients assigned to the placebo, 4.0% of the patients assigned to sulodexide 75 mg daily and 21.4% of those assigned to 150 mg (p=0.308). Treatment with sulodexide 150 mg daily for 6 months significantly reduced log UPCR from 6.38±0.77 at baseline to 5.98±0.94 at 6 months (p=0.045), while treatment with sulodexide 75 mg daily and placebo did not. CONCLUSION: A 6-month treatment with sulodexide did not achieve 50% reduction of urinary protein excretion in IgA nephropathy patients, but showed a tendency to increase the time-dependent anti-proteinuric effect. Therefore, long-term clinical trials on a larger scale are warranted to elucidate the hypothesis that sulodexide affords renal protection in IgA nephropathy patients.


Subject(s)
Anticoagulants/therapeutic use , Glomerulonephritis, IGA/drug therapy , Glycosaminoglycans/therapeutic use , Proteinuria/drug therapy , Adult , Double-Blind Method , Female , Glomerulonephritis, IGA/complications , Humans , Male , Middle Aged , Proteinuria/complications
11.
Inflamm Res ; 60(8): 791-800, 2011 Aug.
Article in English | MEDLINE | ID: mdl-21509626

ABSTRACT

OBJECTIVE: NADPH oxidase is potentially associated with acute pancreatitis by producing reactive oxygen species (ROS). We investigated whether NADPH oxidase mediates the activation of Janus kinase (Jak)2/signal transducers and activators of transcription (Stat)3 and mitogen-activated protein kinases (MAPKs) to induce the expression of transforming growth factor-ß1 (TGF-ß1) in cerulein-stimulated pancreatic acinar cells. TREATMENT: AR42J cells were treated with an NADPH oxidase inhibitor diphenyleneiodonium (DPI) or a Jak2 inhibitor AG490. Other cells were transfected with antisense or sense oligonucleotides (AS or S ODNs) for NADPH oxidase subunit p22(phox) or p47(phox). METHODS: TGF-ß1 was determined by enzyme-linked immonosorbent assay. STAT3-DNA binding activity was measured by electrophoretic mobility shift assay. Levels of MAPKs as well as total and phospho-specific forms of Jak1/Stat3 were assessed by Western blot analysis. RESULTS: Cerulein induced increases in TGF-ß1, Stat3-DNA binding activity and the activation of MAPKs in AR42J cells. AG490 suppressed these cerulein-induced changes, similar to inhibition by DPI. Cerulein-induced activation of Jak2/Stat3 and increases in MAPKs and TGF-ß1 levels were inhibited in the cells transfected with AS ODN for p22(phox) and p47(phox) compared to S ODN controls. CONCLUSION: Inhibition of NADPH oxidase may be beneficial for prevention and treatment of pancreatitis by suppressing Jak2/Stat3 and MAPKs and expression of TGF-ß1 in pancreatic acinar cells.


Subject(s)
Enzyme Activation , Janus Kinase 2/metabolism , Mitogen-Activated Protein Kinases/metabolism , NADPH Oxidases/metabolism , Pancreatitis/physiopathology , STAT3 Transcription Factor/metabolism , Transforming Growth Factor beta1/metabolism , Animals , Cell Line , Ceruletide/pharmacology , Enzyme Inhibitors/metabolism , Humans , NADPH Oxidases/genetics , Pancreas, Exocrine/cytology , Pancreas, Exocrine/drug effects , Pancreas, Exocrine/metabolism , Rats , Reactive Oxygen Species/metabolism , Tyrphostins/metabolism
12.
Ann N Y Acad Sci ; 1090: 368-74, 2006 Dec.
Article in English | MEDLINE | ID: mdl-17384281

ABSTRACT

The cholecystokine (CCK) analogue cerulein causes pathophysiological, morphological, and biochemical events similar to various aspects of human pancreatitis. Doses of CCK or cerulein beyond those that cause the maximum pancreatic secretion of amylase and lipase result in pancreatitis, which is characterized by a dysregulation of the digestive enzyme production and cytoplasmic vacuolization and the death of acinar cells, edema formation, and an infiltration of inflammatory cells into the pancreas. This study aims to investigate whether cerulein induces IL-8 expression in pancreatic acinar cells, and whether cerulein-induced IL-8 expression is inhibited in the cells transfected with mutant genes for c-jun (TAM-67), or IkappaBalpha (MAD-3) or treated inhibitors of mitogen-activated protein kinases (MAPKs). As a result, cerulein induced IL-expression, which was inhibited in the cells transfected with TAM-67 or MAD-3 or treated inhibitors of MAPK. In conclusion, activation of MAPK, nuclear factor-kappaB (NF-kappaB), and activator protein-1 (AP-1) may be the upstream signaling for cerulein-induced IL-8 expression in pancreatic acinar cells.


Subject(s)
Ceruletide/pharmacology , Interleukin-8/metabolism , Mitogen-Activated Protein Kinases/metabolism , NF-kappa B/metabolism , Pancreas/drug effects , Transcription Factor AP-1/metabolism , Animals , Base Sequence , Cell Line , DNA Primers , Mitogen-Activated Protein Kinases/antagonists & inhibitors , Pancreas/cytology , Pancreas/enzymology , Pancreas/metabolism , Protein Kinase Inhibitors/pharmacology , Rats , Reverse Transcriptase Polymerase Chain Reaction
SELECTION OF CITATIONS
SEARCH DETAIL
...